Diagnostics Co. Alere To Acquire EScreen For $270M

Law360, New York (February 28, 2012, 1:27 PM EST) -- Health management company Alere Inc. has agreed to purchase toxicology screening company eScreen Inc. for $270 million in a move to strengthen its position in the diagnostics market, Alere announced Tuesday.

Alere, headquartered in Waltham, Mass., has signed a binding agreement to buy Kansas-based eScreen — which produces employee drug-screening tools — for $270 million with possible additional payments of up to $70 million based on certain conditions, Alere said.

Subject to customary closing regulations, the deal is expected to close within 45 days, Alere said....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.